Neurotransmitter-Mimicking Nanovesicles Facilitate Postoperative Glioblastoma Stem Cell-Specific Treatment for Preventing Tumor Recurrence

Fuming Liang; Qing You; Bin Yu; Chen Wang; Yanlian Yang; Ling Zhu; Zhaohui He

doi:10.1002/advs.202409713

Neurotransmitter-Mimicking Nanovesicles Facilitate Postoperative Glioblastoma Stem Cell-Specific Treatment for Preventing Tumor Recurrence

Adv Sci (Weinh). 2024 Dec 25:e2409713. doi: 10.1002/advs.202409713. Online ahead of print.

Authors

Fuming Liang^{1

2

3}, Qing You^{2

4}, Bin Yu⁵, Chen Wang^{2

3}, Yanlian Yang^{2

3}, Ling Zhu^{2

3}, Zhaohui He¹

Affiliations

¹ Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, 1 Friendship Road, Chongqing, 400016, P. R. China.
² CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, P. R. China.
³ University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
⁴ Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
⁵ Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, 1 Friendship Road, Chongqing, 400016, P. R. China.

PMID: 39721005
DOI: 10.1002/advs.202409713

Abstract

Survival quality of glioblastoma (GBM) patients remains undesirable despite the aggressive multimodal treatment methods implemented, which are strongly associated with tumor recurrence after surgical resection. Self-renewal and strong tumourigenic capacity of glioblastoma stem cells (GSCs) at the narrow margin of the incision are essential factors driving tumor secondary strikes. Currently, the challenges in treating postoperative residual GSCs are mainly due to the lack of materials for incision and GSCs targeting. In this study, a neurotransmitter-mimicking nanovesicle (PMVS-P) based on platelet membrane-derived vesicle (PMV) with anti-GSC drug salinomycin (SAL)-loading and polydopamine (PDA)-surface is synthesized. PMVS-P exhibits surgical incision targeting ability and specifically identified GSCs with highly expressed D2 dopamine receptor (D2DR), a central nervous system neurotransmitter receptor, thus suppressing GBM recurrence. This neurotransmitter-mimicking nanovesicle primed GSC-specific tumoricidal treatment with broadened applications for preventing tumor recurrence.

Keywords: D2DR; glioblastoma recurrences; glioblastoma stem cell inhibitions; neurotransmitter mimickings.

Abstract

Grants and funding